BRIEF published on 01/07/2026 at 19:17, 1 month 29 days ago ABIONYX Pharma's Half-Yearly Review of Liquidity Contract Liquidity Contract TP ICAP Europe Stock Market Transactions ABIONYX Pharma Stocks And Cash
PRESS RELEASE published on 01/07/2026 at 19:12, 1 month 29 days ago Inside Information / Other news releases ABIONYX Pharma releases half-yearly report on liquidity contract with TP ICAP (Europe) SA, detailing shares and cash balance for 2025 Liquidity Contract Shares TP ICAP Cash Balance ABIONYX Pharma
BRIEF published on 12/16/2025 at 21:23, 2 months 20 days ago ABIONYX Pharma Announces €1.8 Million Capital Increase Capital Increase Subscription Rights Euronext Listing ABIONYX Pharma Financial Visibility
BRIEF published on 12/16/2025 at 21:23, 2 months 20 days ago ABIONYX Pharma Announces a Capital Increase Fundraising Capital Increase Biopharmaceutical ABIONYX Pharma Sepsis
PRESS RELEASE published on 12/16/2025 at 21:18, 2 months 20 days ago Inside Information / Other news releases ABIONYX Pharma launches €1.8m capital increase with removal of preferential subscription rights, subscription price at 3.10 euros for new shares, extending financial visibility until 2026 Capital Increase Biopharma Preferential Subscription Rights ABIONYX Pharma Financial Visibility
BRIEF published on 12/05/2025 at 18:05, 3 months ago ABIONYX Reports Monthly Voting Rights and Share Data Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
PRESS RELEASE published on 12/05/2025 at 18:00, 3 months ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 3 months 10 days ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 3 months 10 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 3 months 23 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
Published on 03/05/2026 at 20:00, 2 hours 30 minutes ago PPX Hosts Medical Outreach Campaign for Local Communities
Published on 03/05/2026 at 17:55, 4 hours 35 minutes ago ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 8 hours 30 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 8 hours 30 minutes ago GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 8 hours 30 minutes ago Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 19:49, 2 hours 40 minutes ago EQS-Adhoc: Northern Data Announces Preliminary Q4 2025 revenue and FY 2026 outlook
Published on 03/05/2026 at 19:15, 3 hours 14 minutes ago Huawei Wins Eight GLOMO Awards at MWC Barcelona 2026
Published on 03/05/2026 at 19:05, 3 hours 24 minutes ago Supercharging Edge AI: Apacer Launches Industrial Grade Storage for Raspberry Pi Platforms
Published on 03/05/2026 at 18:40, 3 hours 50 minutes ago 2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 3 hours 55 minutes ago Mersen: Number of shares and voting rights as of February 28, 2026
